Tiziana Life Sciences Ltd (TLSA) — Titan Protect Analysis

TLSA

Tiziana Life Sciences Ltd

Healthcare · ·

$1.24

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$169M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-6.64

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-924.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$9.02

+627% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 1 analysts covering this stock

About Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a

https://www.tizianalifesciences.com

Country: United Kingdom Employees: 10 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.597

Good returns relative to risk taken

Kelly Fraction

-0.0080

No positive edge detected — the data suggests staying out

Calmar Ratio

0.219

Drawdown risk outweighs the returns — higher risk profile

Annual Return

12.2%

Historical annualised return based on price data

Max Drawdown

-55.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

193

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.40

Very low correlation to market moves

52W High

$2.60

52% below the year high

52W Low

$1.14

9% above the year low

Avg Volume

185,903

Average daily shares traded — higher means easier to buy and sell

Short Ratio

8.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.16

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

876.92

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-5,476,750

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-18,431,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$9.02

Target Median

$9.02

Target Low

$9.02

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go